131 related articles for article (PubMed ID: 36911742)
1. Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data.
Li M; Gao X; Wang X
Front Immunol; 2023; 14():1090838. PubMed ID: 36911742
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer.
Wei C; Li M; Lin S; Xiao J
Biomed Res Int; 2022; 2022():4006507. PubMed ID: 35601155
[TBL] [Abstract][Full Text] [Related]
3. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.
Li F; Wang S; Wang Y; Lv Z; Jin D; Yi H; Fu L; Zhai S; Xiao T; Mao Y
Front Immunol; 2023; 14():1101649. PubMed ID: 36845145
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma.
Zhang C; Dang D; Liu C; Wang Y; Cong X
J Cancer; 2021; 12(8):2440-2449. PubMed ID: 33758620
[No Abstract] [Full Text] [Related]
5. Large-Scale Cancer Genomic Analysis Reveals Significant Disparities between Microsatellite Instability and Tumor Mutational Burden.
Choi J; Park KH; Kim YH; Sa JK; Sung HJ; Chen YW; Chen Z; Li C; Wen W; Zhang Q; Shu XO; Zheng W; Kim JS; Guo X
Cancer Epidemiol Biomarkers Prev; 2024 May; 33(5):712-720. PubMed ID: 38393316
[TBL] [Abstract][Full Text] [Related]
6. STING signalling compensates for low tumour mutation burden to drive anti-tumour immunity.
Tan J; Egelston CA; Guo W; Stark JM; Lee PP
EBioMedicine; 2024 Mar; 101():105035. PubMed ID: 38401418
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of immediate early response 5 like (IER5L) in the prognosis and immune checkpoint blockade therapy of non-small cell lung cancer patients.
Wang N; Tan X; Cao S; Liu M
Pathol Res Pract; 2024 Apr; 256():155270. PubMed ID: 38552564
[TBL] [Abstract][Full Text] [Related]
8. Identifying survival of pan-cancer patients under immunotherapy using genomic mutation signature with large sample cohorts.
Zhang L; Wang Y; Wang L; Wang M; Li S; He J; Ji J; Li K; Cao L
J Mol Med (Berl); 2024 Jan; 102(1):69-79. PubMed ID: 37978056
[TBL] [Abstract][Full Text] [Related]
9. Death associated protein kinase 1 predicts the prognosis and the immunotherapy response of various cancers.
Yang J; Liu Y; Geng Q; Wang B
Mol Biol Rep; 2024 May; 51(1):670. PubMed ID: 38787485
[TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Multiomics Analysis of TC2N Gene Suggests its Important Role(s) in Tumourigenesis of Many Cancers.
Qureshi MA; Khan S; Tauheed MS; Syed SA; Ujjan ID; Lail A; Sharafat S
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3199-3209. PubMed ID: 33247676
[TBL] [Abstract][Full Text] [Related]
11. Spatial heterogeneity and organization of tumor mutation burden with immune infiltrates within tumors based on whole slide images correlated with patient survival in bladder cancer.
Xu H; Clemenceau JR; Park S; Choi J; Lee SH; Hwang TH
J Pathol Inform; 2022; 13():100105. PubMed ID: 36268064
[TBL] [Abstract][Full Text] [Related]
12. Integrative analysis of homologous recombination repair patterns unveils prognostic signatures and immunotherapeutic insights in breast cancer.
Li YS; Jiang HC
J Appl Genet; 2024 Mar; ():. PubMed ID: 38478326
[TBL] [Abstract][Full Text] [Related]
13. Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles.
Ling B; Ye G; Zhao Q; Jiang Y; Liang L; Tang Q
Front Mol Biosci; 2020; 7():603701. PubMed ID: 33505988
[No Abstract] [Full Text] [Related]
14. A comprehensive analysis of clinical and polygenic germline influences on somatic mutational burden.
Taraszka K; Groha S; King D; Tell R; White K; Ziv E; Zaitlen N; Gusev A
Am J Hum Genet; 2024 Feb; 111(2):242-258. PubMed ID: 38211585
[TBL] [Abstract][Full Text] [Related]
15. Predicting gastric cancer tumor mutational burden from histopathological images using multimodal deep learning.
Li J; Liu H; Liu W; Zong P; Huang K; Li Z; Li H; Xiong T; Tian G; Li C; Yang J
Brief Funct Genomics; 2024 May; 23(3):228-238. PubMed ID: 37525540
[TBL] [Abstract][Full Text] [Related]
16. Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy.
Qian ZY; Pan YQ; Li XX; Chen YX; Wu HX; Liu ZX; Kosar M; Bartek J; Wang ZX; Xu RH
Sci Bull (Beijing); 2024 Mar; 69(6):803-822. PubMed ID: 38320897
[TBL] [Abstract][Full Text] [Related]
17. Are we ready to use TMB in breast cancer clinical practice?
Ravaioli S; Limarzi F; Tumedei MM; Palleschi M; Maltoni R; Bravaccini S
Cancer Immunol Immunother; 2020 Oct; 69(10):1943-1945. PubMed ID: 32725361
[TBL] [Abstract][Full Text] [Related]
18. Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.
Zhang H; Lee S; Muthakana RR; Lu B; Boone DN; Lee D; Wang XS
Cancer Immunol Res; 2024 Mar; 12(3):287-295. PubMed ID: 38345376
[TBL] [Abstract][Full Text] [Related]
19. A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy.
Bigelow E; Saria S; Piening B; Curti B; Dowdell A; Weerasinghe R; Bifulco C; Urba W; Finkelstein N; Fertig EJ; Baras A; Zaidi N; Jaffee E; Yarchoan M
Cancer Inform; 2022; 21():11769351221136081. PubMed ID: 36439024
[TBL] [Abstract][Full Text] [Related]
20. Identification of gastric cancer subtypes based on pathway clustering.
Li L; Wang X
NPJ Precis Oncol; 2021 Jun; 5(1):46. PubMed ID: 34079012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
